Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or
the "Company"), a clinical-stage biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, announces its
participation in the upcoming Psychedelic Medicine – Israel 2024
conference. This event will take place in Tel Aviv, Israel from
July 28th to 30th, bringing together leading experts and
researchers from around the world in the field of psychedelic
medicine.
Clearmind’s CEO, Adi Zullof-Shani, Ph.D., will present a
compelling talk titled “5-Methoxy-2-Aminoindane (MEAI) as a Binge
Behavior Regulator.” This presentation is scheduled for Monday,
July 29th, in the Research Presentations 1 session, from 9:00 a.m.
to 10:40 a.m. IDT. Dr. Zullof-Shani will provide insights into
MEAI’s potential to regulate binge behaviors, highlighting its
innovative application in treating addiction-related disorders.
Additionally, esteemed researchers Prof. Joseph Tam and Dr. Saja
Baraghithy from the Obesity and Metabolism Laboratory in The Hebrew
University of Jerusalem, will present their abstract titled
“5-methoxy-2-aminoindane (MEAI), a mild psychedelic agent,
attenuates diet-induced obesity.” This presentation is scheduled
for Tuesday, July 30th, in the Research Presentations 3 session,
from 2:00 p.m. to 4:05 p.m. IDT. Their presentation will delve into
the promising results of MEAI in attenuating obesity and its
related metabolic complications, showcasing its potential as a
therapeutic agent in obesity management.
About the Presentations:
5-Methoxy-2-Aminoindane (MEAI) as a Binge Behavior
Regulator
Dr. Zullof-Shani will discuss the unique properties of MEAI, a
psychoactive aminoindane derivative. MEAI has shown promise in
reducing the desire to consume alcoholic beverages while inducing a
euphoric, alcohol-like slightly tipsy but controlled experience.
This presentation will explore MEAI’s potential as a regulator of
binge behaviors, providing a novel approach to addiction
treatment.
5-methoxy-2-Aminoindane (MEAI), a Mild Psychedelic
Agent, Attenuates Diet-induced Obesity
Dr. Baraghithy will present her research findings on the weight
loss effects of MEAI. The study demonstrated that MEAI
significantly reduces overweight and adiposity in a diet-induced
obesity (DIO) mouse model. The researchers will share compelling
evidence that MEAI reduces fat mass, preserves lean mass, improves
glucose metabolism, reduces hepatic steatosis, and increases energy
expenditure, making it a promising therapeutic candidate for
obesity management.
Dr. Zullof-Shani, CEO of Clearmind Medicine, commented, "We are
honored to present our groundbreaking research at the Psychedelic
Medicine – Israel 2024 conference. MEAI has shown remarkable
potential in regulating several binge behaviors and treating
overweight, and we are excited to share these findings with the
scientific community. Our commitment to pioneering research in
psychedelic-derived therapeutics continues to drive us forward as
we seek to address major health challenges."
Psychedelic Medicine – Israel 2024 will provide an
interdisciplinary international forum for exchanging ideas,
unveiling innovations and training in the basics of psychedelic
assisted psychotherapy. The conference will encompass basic,
translational and clinical research. A richly varied program will
include Plenary Lectures, Thematic Symposia, Poster Sessions,
Workshops and informal Salons for discussion and interaction.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech
company focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual portfolio currently consists of
eighteen patent families including 28 granted patents. The Company
intends to seek additional patents for its compounds whenever
warranted and will remain opportunistic regarding the acquisition
of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the
symbol "CMND" and the Frankfurt Stock Exchange under the symbol
“CWY0.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relationsinvest@clearmindmedicine.com
Telephone: (604) 260-1566US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. Forward-looking statements are not
historical facts, and are based upon management’s current
expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no
assurance that management’s expectations, beliefs and projections
will be achieved, and actual results may differ materially from
what is expressed in or indicated by the forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual performance or results to
differ materially from those expressed in the forward-looking
statements. For a more detailed description of the risks and
uncertainties affecting the Company, reference is made to the
Company’s reports filed from time to time with the Securities and
Exchange Commission (“SEC”), including, but not limited to, the
risks detailed in the Company’s annual report on Form 20-F for the
fiscal year ended October 31, 2023 filed with the SEC.
Forward-looking statements speak only as of the date the statements
are made. The Company assumes no obligation to update
forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other
factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update
one or more forward-looking statements, no inference should be
drawn that the Company will make additional updates with respect
thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Clearmind is not
responsible for the contents of third-party websites.
Clearmind Medicine (NASDAQ:CMND)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Clearmind Medicine (NASDAQ:CMND)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024